The cited evidence does not establish a testosterone boost from tesamorelin. Egrifta’s label describes GH and IGF-1 effects and reports no clinically significant change in LH; that is not a direct testosterone treatment result [1].
What tesamorelin does to your hormones
Tesamorelin binds the same receptor as your own GHRH and stimulates pulsatile release of growth hormone. The label describes the growth hormone released as "both anabolic and lipolytic", meaning it builds tissue and frees stored fat [1].
Growth hormone then works partly through IGF-1, a hormone made mainly in the liver [1]. That is the principal pathway described in the label; it does not establish an increase in testosterone.
Does it change testosterone or LH?
The Egrifta label reports no clinically significant changes in other pituitary hormones, including LH, TSH, ACTH and prolactin [1].
No clinically significant changes in the levels of other pituitary hormones, including thyroid-stimulating hormone (TSH), luteinizing hormone (LH), adrenocorticotropic hormone (ACTH) and prolactin, were observed in patients receiving EGRIFTA in clinical trials.[1]
LH signals the testes to produce testosterone. The absence of a clinically significant LH change does not establish that every downstream sex-hormone effect is impossible; it means these label findings do not demonstrate a testosterone benefit.
Testosterone isn't one of the outcomes the label or the pivotal trial reports [2]. A PubMed search for tesamorelin and testosterone returned a single 2010 review of belly fat in HIV, not a trial [4].
| Hormone | Effect | Source |
|---|---|---|
| Growth hormone | Stimulates pulsatile release | Egrifta SV label, section 12.1 |
| IGF-1 | +81.0% vs −5.0% on placebo, 26 weeks | Falutz 2007 [2] |
| LH (drives testosterone) | No clinically significant change | Label, section 12.2 |
| TSH, ACTH, prolactin | No clinically significant change | Label, section 12.2 |
| Testosterone | Not reported as changed | Label and published trials |
Is tesamorelin a growth hormone?
No. It's a synthetic version of the hormone that tells the pituitary to release growth hormone, so the growth hormone is made by your own body [1].
Growth hormone itself is a different drug, somatropin, given as the hormone directly. Tesamorelin works one step upstream, which is why your body's own feedback on the pituitary still applies.
The hormone it does raise: IGF-1
In the pivotal trial of 412 adults with HIV, IGF-1 rose 81% on tesamorelin while it fell 5% on placebo over 26 weeks [2]. In a pooled look at two phase 3 trials, mean IGF-1 rose by 108 ng/mL against a small fall on placebo [3].
That rise is common, not rare. Among people on the drug for 26 weeks, 47% had IGF-1 above 2 standard deviation scores and 36% above 3, some as early as week 13 [1].
Other hormone-related effects on the label
Two other label warnings tie back to growth hormone. Neither involves testosterone, but both matter if you're weighing the drug.
- Fluid retention. Swelling, joint pain and carpal tunnel symptoms can occur, and they're usually temporary or resolve when the drug stops [1].
- Blood sugar. By week 26, 5% of people on tesamorelin vs 1% on placebo had an HbA1c of 6.5% or higher, the diabetes range [1].
The label asks prescribers to check blood sugar before starting and periodically after. That's another reason this drug is prescribed and followed by a clinician, not bought online.
Why "boosts testosterone" claims spread
Growth hormone and sex hormones do interact, which is where the confusion starts. The label notes growth hormone may change how the liver clears drugs processed by CYP450 enzymes, a list that includes "sex steroids" [1].
That's a drug-interaction note for prescribers, not a testosterone increase. It tells them to watch for interactions when tesamorelin is combined with those drugs. For what's known about pairing it with other compounds, see the legal status of combining tesamorelin.
The same confusion follows sermorelin, an older GHRH analog. Its own page covers whether sermorelin raises testosterone. If muscle is the real goal, see what tesamorelin trials show about muscle.
If low testosterone is your concern
Blood tests and a prescriber visit are the first step. Testosterone therapy is the treatment with an FDA label for low testosterone [5].
That label covers men whose low testosterone has an identified medical cause, such as testicular failure or a pituitary or hypothalamus problem. Its safety and effectiveness in age-related low testosterone haven't been established [5].
Read what testosterone therapy is, or start with the hormones shortlist. Ask for your results in writing so you can compare them over time.
Where tesamorelin stands
Tesamorelin is FDA-approved as Egrifta, for excess belly fat in adults with HIV-associated lipodystrophy. Two formulations exist, Egrifta SV and Egrifta WR, and they aren't interchangeable [1].
Since March 23, 2020, FDA has regulated it as a biologic, and biologics can't be compounded under the usual pharmacy exemptions [6]. For more, see tesamorelin's legal status and whether it affects appetite.